Tero Satomaa

Mr. Tero Satomaa

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2009 in BMC Cell Biology
Verified
Journal Article
Open access
PDF file
TSTero Satomaa
Tero Satomaa
AHAnnamari Heiskanen
Annamari Heiskanen
MMMilla Mikkola
Milla Mikkola
COCia Olsson
Cia Olsson
MBMaria Blomqvist
Maria Blomqvist
JLJarmo Laine
Jarmo Laine
Complex carbohydrate structures, glycans, are essential components of glycoproteins, glycolipids, and proteoglycans. While individual glycan structures including the SSEA and Tra antigens are already used to define undifferentiated human embryonic stem cells (hESC), the whole spectrum of stem cell glycans has remained unknown. We undertook a global study of the asparagine-linked glycoprotein glycans (N-glycans) of hESC and their differentiated progeny using MALDI-TOF mass spectrometric and NMR spectroscopic profiling. Structural analyses were performed by specific glycosidase enzymes and mass spectrometric fragmentation analyses.

15 July 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
TSTero Satomaa
Tero Satomaa
AHAnnamari Heiskanen
Annamari Heiskanen
ILIréne Leonardsson
Iréne Leonardsson
JAJonas Ångström
Jonas Ångström
AOAnne Olonen
Anne Olonen
JSJuhani Saarinen
Juhani Saarinen
The cell surface is covered by a dense layer of protein- and lipid-linked glycans. Although it has been known that distinct glycan structures are associated with cancer, the whole spectrum of cancer-associated glycans has remained undiscovered. In the present study, we analyzed the protein-linked cancer glycome by matrix-assisted laser desorption/ionization time-of-flight mass spectrometric glycan profiling of cancer patient tissue samples. In lung cancer, we detected accumulation of a novel group of tumor-associated glycans. These protein-linked glycans carried abnormal nonreducing terminal β-N-acetyl-d-glucosamine (GlcNAc) residues. A similar phenomenon was also detected in structural analyses of tumor-derived glycosphingolipids. This showed that glycan biosynthesis may dramatically change in cancer and that direct glycome analysis can detect the resulting marker glycans. Based on the structural knowledge, we further devised a covalent labeling technique for the detection of GlcNAc-expressing tumors with a specific transferase enzyme. In normal tissues, terminal GlcNAc antigens are capped by galactosylation. Similarly to common cancer-associated glycan antigens T, Tn, and sialyl-Tn, the newly discovered GlcNAc antigens result from incomplete glycosylation. In conclusion, the identified terminal GlcNAc glycans should be recognized as a novel class of tumor markers. [Cancer Res 2009;69(14):5811–9]

22 March 2018 in Antibodies
Verified
Journal Article
Open access
PDF file
TSTero Satomaa
Tero Satomaa
HPHenna Pynnönen
Henna Pynnönen
AVAnja Vilkman
Anja Vilkman
TKTitta Kotiranta
Titta Kotiranta
VPVirve Pitkänen
Virve Pitkänen
JSJuhani Saarinen
Juhani Saarinen
Antibody-drug conjugates (ADCs) offer a combination of antibody therapy and specific delivery of potent small-molecule payloads to target cells. The properties of the ADC molecule are determined by the balance of its components. The efficacy of the payload component increases with higher drug-to-antibody ratio (DAR), while homogeneous DAR = 8 ADCs are easily prepared by conjugation to the four accessible antibody hinge cystines. However, use of hydrophobic payloads has permitted only DAR = 2–4, due to poor pharmacokinetics and aggregation problems. Here, we describe generation and characterization of homogeneous DAR = 8 ADCs carrying a novel auristatin β-D-glucuronide, MMAU. The glycoside payload contributed to overall hydrophilicity of the ADC reducing aggregation. Compared to standard DAR = 2–4 ADCs, cytotoxicity of the homogeneous DAR = 8 ADCs was improved to low-picomolar IC50 values against cancer cells in vitro. Bystander efficacy was restored after ADC internalization and subsequent cleavage of the glycoside, although unconjugated MMAU was relatively non-toxic to cells. DAR = 8 MMAU ADCs were effective against target antigen-expressing xenograft tumors. The ADCs were also studied in 3D in vitro patient-derived xenograft (PDX) assays where they outperformed clinically used ADC. In conclusion, increased hydrophilicity of the payload contributed to the ADC’s hydrophilicity, stability and safety to non-target cells, while significantly improving cytotoxicity and enabling bystander efficacy.

27 October 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
FEFilip S. Ekholm
Filip S. Ekholm
HPHenna Pynnönen
Henna Pynnönen
AVAnja Vilkman
Anja Vilkman
VPVirve Pitkänen
Virve Pitkänen
JHJari Helin
Jari Helin
TSTero Satomaa
Tero Satomaa

24 December 2018 in Separations
Verified
Journal Article
Open access
PDF file
FEFilip Ekholm
Filip Ekholm
SRSuvi-Katriina Ruokonen
Suvi-Katriina Ruokonen
MRMarina Redón
Marina Redón
VPVirve Pitkänen
Virve Pitkänen
AVAnja Vilkman
Anja Vilkman
SWSusanne Wiedmer
Susanne Wiedmer
Antibody-drug conjugates (ADCs) are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. The idea behind the ADC technology is remarkable as it combines the highly selective targeting capacity of monoclonal antibodies with the cancer-killing ability of potent cytotoxic agents. The continuous development of improved ADCs requires systematic studies on the nature and effects of warhead modification. Recently, we focused on the hydrophilic modification of monomethyl auristatin E (MMAE), the most widely used cytotoxic agent in current clinical trial ADCs. Herein, we report on the use of micellar electrokinetic chromatography (MEKC) for studying the hydrophobic character of modified MMAE derivatives. Our data reveal a connection between the hydrophobicity of the modified warheads as free molecules and their cytotoxic activity. In addition, MMAE-trastuzumab ADCs were constructed and evaluated in preliminary cytotoxic assays.

2 December 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
FEFilip Ekholm
Filip Ekholm
HPH. Pynnönen
H. Pynnönen
AVA. Vilkman
A. Vilkman
JKJ. Koponen
J. Koponen
JHJ. Helin
J. Helin
TSTero Satomaa
Tero Satomaa
The water soluble copper chelator TGTA was found to be a suitable protective agent against copper induced degradation of biomolecules.